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ABSTRACT
Introduction. Recombinant human erythropoietin (r-HuEPO) is used to treat symptomatic anaemia due to che-
motherapy. A new r-HuEPO, Epoetin theta (Eporatio
®), was investigated and compared to placebo in a randomised,
double-blind clinical trial in adult cancer patients receiving nonplatinum-based chemotherapy. The primary efﬁcacy
endpoint was the responder rate (complete haemoglobin (Hb) response, i.e., Hb increase 2 g/dl) without the
beneﬁt of a transfusion within the previous 4 weeks.
Research Design and Methods. 186 patients were randomised to s.c. treatment for 12 weeks with either Epoetin
theta (N = 95) or placebo (N = 91). The starting dose was 20,000 IU once weekly Epoetin theta or placebo.
Results. The incidence of complete Hb responders was signiﬁcantly higher in the Epoetin theta group than in the
placebo group (72.6 vs. 25.3%, P < 0.0001). More patients in the placebo group than in the Epoetin theta group
received blood transfusions after randomisation (23 patients, 25.3% vs. 13 patients, 13.7%, P = 0.0277). The
majority of patients with a complete Hb response had 20,000 IU/week as their maximum dose prior to response,
indicating that a dose of 20,000 IU is an appropriate starting dose. The overall frequencies of adverse events (AEs)
were similar in both treatment groups. Hypertension was the only AE that was more frequent in the Epoetin theta
group compared to the placebo group (8.4 vs. 1.1%).
Conclusions. Epoetin theta showed a superior efﬁcacy to placebo in terms of complete Hb response without blood
transfusion within the previous 4 weeks. Treatment with Epoetin theta resulted in a statistically signiﬁcant increase
in mean haemoglobin levels compared to placebo. The overall frequencies of adverse events were similar in both
treatment groups.
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Introduction
C
ancer patients may develop anaemia as a
result of disease characteristics, chemo-
therapy or due to decreased endogenous erythro-
poietin production. Erythropoietin is the essential
growth factor required for the production of
red blood cells from late progenitor cells of the
erythroid lineage in bone marrow. Patients with
reduced or absent endogenous erythropoietin
production may need to receive exogenous eryth-
ropoietin as replacement therapy for the stimula-
tion of erythropoiesis and correction of their
symptomatic anaemia.
33
© 2011, Archives of Drug Information Arch Drug Info 2011;4:33–41Anaemia due to chemotherapy is a major clini-
cal problem and a typical later complication of
chemotherapy treatment. The aims of manage-
ment of this condition are to minimise the use of
blood or red cell transfusions, to eliminate symp-
toms arising from anaemia, to improve quality of
life (QoL) and to minimise secondary effects of
anaemia. Transfusion is the traditional approach to
the management of anaemia. However, growing
concerns about infection risks, and the fact that the
supply of transfusion products is limited has led
to a reduction in the use of red cell transfusions,
opening up a need for alternatives to transfusion.
Recombinant human erythropoietin has been
used in the treatment of anaemia due to chemo-
therapy for more than 20 years [1,2]. All epoetins
are structurally similar and have the same polypep-
tide receptor binding sites. However, there are
subtle differences in the glycosylation patterns of
different types of epoetins.
Epoetin theta which was developed by BioGen-
eriX AG contains recombinant human erythropoi-
etin (r-HuEPO) as the active drug substance and is
structurally similar to other recombinant epoetins.
The starting dose of Epoetin theta is 20,000 IU
subcutaneously (s.c.) once weekly. This starting
dose is lower than the recommended starting dose
of Epoetin beta (30,000 IU per week) and Epoetin
alfa (450 IU/kg per week).
The objective of this study was to demonstrate
superiority of Epoetin theta compared to placebo
for efﬁcacy during the treatment period of 12
weeks in patients with solid tumours or non-
myeloid haematological malignancies receiving
nonplatinum chemotherapy.
Patients and Methods
Patients
A multinational, multicentre, randomised,
placebo-controlled, double-blind phase III study
was performed at 72 study centres in 10 countries.
ThestudywasconductedaccordingtoGoodClini-
cal Practice and the Declaration of Helsinki (1996)
andallpatientssignedinformedconsentbeforeany
study-related activities were performed. The study
protocol, amendments, informed consent docu-
ments and other relevant study-related documents
were reviewed and approved by independent ethics
committees of all participating countries (Argen-
tina, Belarus, Brazil, Bulgaria, Chile, India,
Moldova, Romania, Russia, Ukraine). Between
November 2005 and May 2007 patients with sec-
ondary anaemia related to nonplatinum chemo-
therapy participated in the study. Male and female
patients 18 years of age with histologically or
cytologically proven diagnosis of a solid tumour or
non-myeloid haematological tumour were eligible
for the study if they gave written informed consent
and had anaemia caused by nonplatinum-based
chemotherapy deﬁned by a documented Hb con-
centration of 11 g/dl after the last chemotherapy
priortoinclusion.Furtherinclusioncriteriaamong
others requested that the patients had at least 1
previous nonplatinum-based chemotherapy cycle
as treatment of the current malignancy during the
last 4 weeks and had Eastern Cooperative Oncol-
ogyGroup(ECOG)performancestatus0,1,2or3.
Exclusion criteria were any other primary haema-
tologic disorder that would cause anaemia, head
and neck tumours, uncontrolled severe hyperten-
sion and concomitant radiotherapy. Iron substitu-
tion was allowed during the study.
Study Design
A total of 186 patients were randomised using a
computer-generated allocation schedule in a 1:1
ratio stratiﬁed by country to double blind treat-
ment for 12 weeks with either Epoetin theta
(N = 95) or placebo (N = 91). All persons involved
in the conduct of the study were blinded with
respect to the study medication. Recruitment
period was 15 months and the study ended regu-
larly. Patients randomised to Epoetin theta
received a starting dose of 20,000 IU Epoetin theta
subcutaneously (s.c.) once weekly or the same
volume of placebo. This starting dose was
increased to 40,000 IU/week in patients who did
not have a partial response (Hb increase of 1g /
dl) after 4 weeks of treatment, and again to
60,000 IU/week in case of insufﬁcient response
after the second 4 week period of treatment
(Figure 1). If the patient’s Hb level increased by
more than 2 g/dl in a 4-week period the weekly
dose was reduced by 50%. If the Hb level exceeded
13 g/dl the dose was reduced to 50% of the recent
dose or was temporarily withhold. The selection of
the Epoetin theta doses was based on recent evi-
dence that lower doses than those recommended
for authorised products may achieve a comparable
Hb response, that the same weekly doses adminis-
tered once or three times weekly result in the same
Hb response [3–5] and that ﬁxed doses rather than
weight-based doses can be used in anaemic cancer
patients [6]. Patients randomised to placebo
received s.c. injections of placebo and dose adjust-
ment according to the same schedule as for
Epoetin theta for blinding purposes.
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sured weekly throughout the study. Baseline levels
were deﬁned as the mean of two values measured
prior to initiation of drug treatment. The
FACT-An questionnaire including FACT-G and
-F [7] was used to assess the QoL.
Immunogenicity was assessed by a predeﬁned
cascade of antibody assays. This cascade was struc-
tured into a sequential scheme comprising screen-
ing, conﬁrmation and characterisation of clinical
specimens.Conﬁrmedpositivesampleswereinves-
tigatedforneutralisingantibodiesinacellularassay
using an erythropoietin dependent UT-7 cell line.
Epoetinthetaandplacebowereprovidedinglass
vials. The study drug was administered by appro-
priatelyqualiﬁedstudypersonnel.Theinvestigator
andallotherstudypersonnelwerekeptblindedand
performed all assessments of the patient without
knowledge of treatment. An unblinded indepen-
dent Data Safety Monitoring Committee closely
monitored the safety in order to ensure that
patients were not exposed to an unjustiﬁable risk.
Endpoints
The pre-speciﬁed primary endpoint was the
number of patients with a complete Hb response
which was deﬁned as an increase in Hb of 2 g/dl
from baseline without the beneﬁt of a transfusion
within the previous four weeks. Secondary efﬁcacy
endpoints included the number of patients having
a partial Hb response (deﬁned as increase of
1 g/dl from baseline), the number of patients
having a complete Hb response with the starting
dose, the number of patients having a partial Hb
response with the starting dose, the number of
patients receiving transfusions, the number of
blood units transfused, the time course of Hb,
haematocrit and reticulocytes, the QoL (FACT-
An, including FACT-G and -F [7]), and the dose of
Epoetin theta at the time of complete/partial Hb
response. Blood transfusions were administered on
a case by case basis at the discretion of the inves-
tigator. Transfusions should have been avoided at a
haemoglobin level 8.5 g/dl. Safety endpoints
included safety lab, vital signs, incidence of adverse
events (AEs) and adverse drug reactions (ADRs),
incidence of hypertension, overall tolerability and
screening for anti-drug antibodies to Epoetin
theta at the beginning and end of the study.
Statistical Methods
A logistic regression analysis with treatment
and type of cancer as explanatory and baseline
haemoglobin value as continuos variables was
performed to estimate the difference in the pro-
portion of complete haemoglobin responders
between Epoetin theta and placebo in the conﬁr-
matory analysis of the primary efﬁcacy endpoint.
For the other binary secondary efﬁcacy endpoints
the same logistic regression model as for the
primary endpoint was estimated. Changes of QoL
(FACT-scores) from baseline to end of study were
compared pairwise with the Wilcoxon-Mann-
Whitney test, whereas the treatment groups for
the other secondary efﬁcacy endpoints were only
compared descriptively. Descriptive P-values were
calculated with appropriate statistical tests but
were regarded as supportive only. For the primary
efﬁcacy endpoint a subgroup analysis with type of
malignancy (solid, non-myeloid haematological)
was performed. All descriptive tables were dis-
played by country.
The sample size calculation required the inclu-
sion of 80 patients per treatment group to achieve
a power of 90% for the statistical superiority test
comparing Epoetin theta and placebo assuming a
response rate of 45% for Epoetin theta and 20%
for placebo.
Results
Thedemographicandbaselinecharacteristicswere
comparable across the 2 treatment groups. There
were no relevant differences between treatment
groups with regard to medical history, prior or
concomitant medications, ECOG performance
status, previous chemotherapy, concomitant dis-
eases, and primary malignant disease (Table 1).
There were no clinically noteworthy differences
between the treatment groups with regard to
on-study chemotherapies. In total, 161 (86.6%)
patients completed the study according to protocol
Figure 1 Dose adaptation of Epoetin theta.
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discontinued the study, 15 were in the placebo
groupand10intheEpoetinthetagroup.Themost
common reason for discontinuation was the occur-
rence of an AE (10 patients), followed by patient’s
request (9 patients).
The results of efﬁcacy endpoints for the full
analysis set are summarised in Table 2 (number of
patients with a complete and partial Hb response
without blood transfusion, number of patients
with a complete and partial Hb response without
blood transfusion and with the starting dose and
number of patients receiving blood transfusions)
and Figure 3 (time course of Hb).
Extent of Exposure
The mean  SD average weekly dose was
25,905  10,956 IU in the Epoetin theta group.
The mean treatment duration  SD was compa-
rable in both groups (71.9  16.9 days placebo vs.
72.1  15.7 days Epoetin theta).
Complete Haemoglobin ResponseWithout
BloodTransfusion
The primary parameter for the conﬁrmatory
analysis was the complete Hb response (increase of
2 g/dl from baseline) without blood transfusion.
The responder rate in the Epoetin theta group was
substantially higher than in the placebo group
(72.6 vs. 25.3%). The difference between Epoetin
theta and placebo was statistically signiﬁcant
(P < 0.0001) with a baseline Hb adjusted odds ratio
(OR) of 7.94 (95% CI: 4.18, 15.63) (Table 2). Type
of cancer and baseline haemoglobin levels had no
statistically signiﬁcant effects on the response rate.
The proportion of patients who had a complete
Hb response without changing the starting
dose was signiﬁcantly higher (P < 0.0001, OR:
7.73, 95%CI: 3.59, 18.29) in the Epoetin theta
group than in the placebo group (45.3 vs. 9.9%)
(Table 2). Type of cancer and baseline haemoglo-
bin levels had also no statistically signiﬁcant effects
on the response rate.
Partial Haemoglobin ResponseWithout
BloodTransfusion
The partial Hb response was deﬁned as increase of
1 g/dl from baseline without blood transfusion
within the last four weeks. As for the complete Hb
response, the responder rate was higher with
Epoetin theta than with placebo (82.1 vs. 61.5%,
P = 0.0025, OR: 2.84, 95% CI: 1.46, 5.69)
(Table 2). Type of cancer and baseline haemoglo-
Table 1 Patient characteristics
Placebo
(n = 91)
Epoetin theta
(n = 95)
Total
(n = 186)
Gender [n (%)]
Male 34 (37.4%) 30 (31.6%) 64 (34.4%)
Female 57 (62.6%) 65 (68.4%) 122 (65.6%)
Age [years]
Mean  SD 55.8  14.3 56.9  14.7 56.3  14.5
Median 57.0 60.0 58.0
Range 18.0 to 82.0 18.0 to 83.0 18.0 to 83.0
Body weight [kg]
Mean  SD 68.6  14.1 67.4  15.2 68.0  14.6
Median 68.0 68.0 68.0
Range 41.0 to 103.0 43.0 to 127.0 41.0 to 127.0
ECOG performance status
0 9 (9.9%) 14 (14.7%) 23 (12.4%)
1 60 (65.9%) 53 (55.8%) 113 (60.8%)
2 21 (23.1%) 28 (29.5%) 49 (26.3%)
3 1 (1.1%) 0 1 (0.5%)
Most common malignancies
Multiple myeloma 17 (18.7%) 19 (20.0%) 36 (19.4%)
Breast cancer 17 (18.7%) 16 (16.8%) 33 (17.7%)
Chronic lymphocytic leukaemia 7 (7.7%) 5 (5.3%) 12 (6.5%)
Gastric cancer 3 (3.3%) 6 (6.3%) 9 (4.8%)
Most common on-study CT
Cyclophosphamide 47 (51.6%) 50 (52.6%) 97 (52.2%)
Doxorubicin 29 (31.9%) 32 (33.7%) 61 (32.8%)
Vincristine 28 (30.8%) 26 (27.4%) 54 (29.0%)
Dexamethasone 21 (23.1%) 22 (23.2%) 43 (23.1%)
Prednisolone 26 (28.6%) 14 (14.7%) 40 (21.5%)
Abbreviations: n = number of patients; SD = standard deviation; CT = chemotherapy.
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the response rate. The proportion of patients who
had a partial Hb response without blood transfu-
sion and without changing the starting dose was
signiﬁcantly higher (P < 0.0001, OR: 4.03, 95%
CI: 2.18, 7.63) in the Epoetin theta group com-
pared to placebo (58.9 vs. 26.4%) (Table 2). Type
of cancer and baseline haemoglobin levels had also
no statistically signiﬁcant effects on the partial
response rate.
Number of Patients Receiving BloodTransfusions
More patients in the placebo group than in the
Epoetin theta group received blood transfusions
after randomisation (25.3 vs. 13.7%). The differ-
ence between the treatment groups was statisti-
cally signiﬁcant (P = 0.0277) with an odds ratio of:
0.35 (95% CI: 0.13, 0.87) (Table 2). Baseline hae-
moglobin levels had a statistically signiﬁcant effect
on the rate of blood transfusion (P < 0.0001) with
an odds ratio of 0.32 (95% CI: 0.21, 0.47) per g/dl
baseline Hb. Type of cancer had no statistically
signiﬁcant effect on the rate of blood transfusion.
Number of Blood UnitsTransfused
The mean (SD) number of blood units trans-
fused after randomisation in those patients who
needed a transfusion was 4.1  2.8 units in the
placebo group and 3.5  3.5 units in the Epoetin
theta group.
Time Course of Haemoglobin, Haematocrit
and Reticulocytes
Baseline Hb values were similar in both treatment
groups (Figure 3). Over the course of the study
mean Hb levels rose steadily in the Epoetin theta
group, exceeding 10 g/dl by day 25 and reached
11 g/dl by day 64. The mean  SD Hb levels rose
from 9.2  1.3 g/dl at baseline to 11.3  2.0 g/dl
at the end of the study, resulting in an increase of
2.1 g/dl. In the placebo group, a slight rise in mean
haemoglobin levels was observed over the course
Figure 2 Disposition of patients.
Epoetin Theta and Nonplatinum Chemotherapy 37
Arch Drug Info 2011;4:33–41of the study but the mean level never reached
10 g/dl. Treatment with Epoetin theta resulted in
a statistically signiﬁcant (P < 0.0001) increase in
mean haemoglobin levels by the end of the study
compared to placebo.
The changes of haematocrit values were very
similar to the changes of Hb values over time.
Absolute reticulocyte values showed a high degree
of variability in both treatment groups and at all
timepoints.
Dose of EpoetinTheta at theTime of Partial or
Complete Haemoglobin Response
The mean  SD weekly dose of Epoetin theta at
the time of complete Hb response without blood
transfusion was 27,681.2  14,260.7 IU (median
20,000 IU), and at the time of partial Hb response
it was 24,871.8  10,659.3 IU (median
20,000 IU). The mean dose of Epoetin theta at the
time of complete and partial Hb response was
similar for solid tumours and haematological
malignancies. A dose of up to 20,000 IU/week was
sufﬁcient for complete Hb response in 66.7% of
patients with complete response in the Epoetin
theta group. In a further 23.2% of patients with
complete response, response was achieved with a
dose of 40,000 IU/week.
Quality of Life
The completion rate of valid FACT-An question-
naires was high in both treatment groups: 89.5 to
Table 2 Results of efficacy endpoints
Number of patients with a complete and partial Hb
response without blood transfusion, number of patients
with a complete and partial Hb response without blood
transfusion and with the starting dose and number of
patients receiving blood transfusions for the full analysis set
Placebo
(n = 91)
Epoetin theta
(n = 95)
Baseline Hb [g/dl]
mean  standard deviation
9.1  1.3 9.2  1.3
Complete Hb response without blood transfusion:
N (%) 23 (25.3%) 69 (72.6%)
P value <0.0001
Odds ratio (95% CI) 7.944 (4.182, 15.632)
Complete Hb response without blood transfusion and dose
adjustment:
N (%) 9 (9.9%) 43 (45.3%)
P value <0.0001
Odds ratio (95% CI) 7.728 (3.590, 18.285)
Partial Hb response without blood transfusion:
N (%) 56 (61.5%) 78 (82.1%)
P value 0.0025
Odds ratio (95% CI) 2.841 (1.462, 5.694)
Partial Hb response without blood transfusion and dose
adjustment:
N (%) 24 (26.4%) 56 (58.9%)
P value <0.0001
Odds ratio (95% CI) 4.028 (2.179, 7.632)
Patients received blood transfusions
N (%) 23 (25.3%) 13 (13.7%)
P value 0.0277
Odds ratio (95% CI) 0.352 (0.133, 0.868)
Abbreviations: n = number of patients; Hb = haemoglobin; CI = conﬁdence
interval.
Figure 3 Time course of mean
(SEM) haemoglobin values for the
full analysis set. Epoetin theta
(yellow) and placebo (green).
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the placebo group with only small decreases in
completion rates observed over the course of the
study in both groups. For all scores mean changes
from baseline were in favour of the Epoetin theta
group compared to placebo, however the differ-
ences were not statistically signiﬁcant, considering
that the study was not powered for this compari-
son (Table 3).
Safety Evaluation
The overall frequencies of adverse events (AEs)
were similar in both treatment groups with 78.0%
in the placebo group and 80.0% in the Epoetin
theta group (Table 4). The high incidence of AEs
was to be expected in cancer patients receiving
chemotherapy. The overall proﬁle of the most fre-
quently reported AEs can be expected in the rather
elderly study population of cancer patients receiv-
ing nonplatinum chemotherapy. Frequencies only
exceeded 10% for asthenia (20.4%), neutropenia
(18.8%), nausea (17.2%), leukopenia (15.6%) and
pyrexia (12.9%). Hypertension was the only AE
that was more frequent in the Epoetin theta group
compared to the placebo group (8.4 vs. 1.1%).
Hypertension is the most frequently reported side
effect of treatment with epoetins. Skin reactions
that might have been caused by the subcutaneous
administration of study medication were reported
in 20 patients (13 Epoetin theta, 13.7% and 7
placebo, 7.7%). None of the skin reactions was
severe or serious.
Adverse drug reactions (ADRs) with a causal
relationship to the study medication as assessed
by the investigator were reported in 27 (28.4%)
patients in the Epoetin theta group and 18 (19.8%)
patients in the placebo group (Table 4). The most
common ADRs were asthenia (7.5%), nausea
(5.4%), headache (3.2%), pyrexia (2.7%) and vom-
iting (2.2%). All of these events commonly occur
in cancer patients receiving chemotherapy.
Eleven of the patients in this study (6 Epoetin
theta, 5 placebo) died during the study period
(Table 4). The most frequent reason for death was
disease progression (3 placebo, 2 Epoetin theta).
Serious adverse events (SAEs) were reported in 25
(13.4%) patients (11 Epoetin theta, 14 placebo)
(Table 4). Just 1 of the SAEs (pyrexia in a placebo
patient) was assessed as related to the study medi-
cation. AEs leading to study discontinuation were
reported in 10 patients (4 Epoetin theta, 6 placebo)
and 1 patient in the placebo group discontinued
due to a ADR (thrombophlebitis).
Results for safety lab variables, vital signs, body
weight, 12-lead ECG, physical examination, toler-
ability, skin irritation, and results of current che-
motherapy did not give rise to any safety concerns.
Tolerability as assessed by the patients was very
good or good in 89.5% and 89.0% of patients in
the Epoetin theta and placebo group, respectively.
The investigators assessed tolerability as very good
or good in 98.9% (Epoetin theta) and 96.7%
(placebo) of the patients.
The response rate (complete plus partial
response) to chemotherapy was slightly higher in
the Epoetin theta group (45.3 vs. 40.7%), there-
fore there is no evidence that Epoetin theta could
have had a negative impact on the course of the
disease or on the efﬁcacy of the chemotherapy.
The incidence of anti-drug antibodies to
Epoetin theta was assessed at the beginning and
end of the study. Only 1 patient treated with
placebo developed a single positive result at base-
line. A cellular assay to detect neutralisation was
negative and a blood sample taken from this
placebo-treated patient at the end of the study was
Table 3 Mean changes from baseline in FACT scores
Score type
Placebo
(n = 91)
N valid = 84
Epoetin theta
(n = 95)
N valid = 88
FACT-An Total
Mean  SD 0.6  22.0 6.3  21.7
P value P = 0.243
FACT-An Trial outcome index
Mean  SD 1.2  18.8 5.6  17.1
P value P = 0.222
FACT-F Fatigue module
Mean  SD 0.6  8.8 2.9  7.9
P value P = 0.142
FACT-G Total score
Mean  SD -0.2  12.4 3.0  12.7
P value P = 0.224
Abbreviations: n = number of patients; N valid = number of valid question-
naires; SD = standard deviation; FACT-An = Functional Assessment of
Cancer Therapy—Anaemia scale; FACT-F = Functional Assessment of
Cancer Therapy—Fatigue scale; FACT-G = Functional Assessment of Cancer
Therapy—General scale.
Table 4 Frequencies of AE categories (full analysis set)
Category of AE
Placebo
(n = 91)
Epoetin theta
(n = 95) Total (n = 186)
n% n % n %
Any AE 71 78.0 76 80.0 147 79.0
Related AE = ADR 18 19.8 27 28.4 45 24.2
Serious AE 14 15.4 11 11.6 25 13.4
Serious ADR 1 1.1 0 — 1 0.5
Death 5 5.5 6 6.3 11 5.9
Abbreviations: n = number of patients; multiple mentions per patient are
possible.
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study developed neutralising anti-epoetin antibod-
ies to Epoetin theta.
Discussion
The selection of the weekly ﬁxed starting dose of
20,000 IU Epoetin theta, which is lower than the
recommended starting dose of other epoetins, is in
line with recent recommendations for the treat-
ment of cancer patients with epoetins, i.e., to use
the lowest dose needed to avoid red blood cell
transfusion [8].
A meta-analysis based on 14 randomised con-
trolled trials including 2,347 cancer patients, with
haematologic response to treatment with erythro-
poietin deﬁned as an increase in Hb of at least
2 g/dl unrelated to transfusion, reported response
rates of 9–70% [9]. The corresponding relative
risk (RR) for haematologic response in the eryth-
ropoietin group was 3.60 (95% CI: 3.07, 4.23).
Thus, patients receiving an erythropoietin are 3 to
4 times more likely to achieve Hb response. The
response rates of 72.6% in the Epoetin theta group
and 25.3% in the placebo group observed in this
study therefore is in line with the literature,
although the weekly starting dose was ﬁxed and
not body weight adjusted and lower than the
weekly dose in the studies included in the above
meta-analysis.
A key clinical factor in the treatment of anaemia
due to chemotherapy is reduction in the need for
blood transfusions. A meta-analysis based on 25
randomised controlled trials including 3,069
cancer patients showed that the use of erythropoi-
etin signiﬁcantly reduced the relative risk of red
blood cell transfusion (RR 0.67, 95% CI: 0.62,
0.73) [9]. In the present study, a signiﬁcantly lower
proportion of patients in the Epoetin theta group
than in the placebo group received blood transfu-
sions after randomisation (13.7 vs. 25.3%,
P = 0.0277).
The results of the present study is in line with
information derived from the literature. This
holds true also for the further efﬁcacy parameters
like the haemoglobin and haematocrit levels over
time. A total of 66.7% of the complete responders
in the Epoetin theta group achieved the response
with the starting dose of 20,000 IU/week. This
conﬁrms that the Epoetin theta dosing schedule
tested here is suitable for an effective and well
tolerated treatment of anaemic cancer patients.
The frequencies and types of AEs as observed in
this study were to be expected in cancer patients
receiving chemotherapy. Furthermore, no anti-
drug antibodies to Epoetin theta were detected in
any patient of this study.
Results for other safety parameters like SAEs,
AEs leading to discontinuation, safety lab vari-
ables, vital signs, etc. did not give rise to any safety
concerns.
Conclusions
Epoetin theta with a weekly starting dose of
20,000 IU is superior to placebo in terms of com-
plete Hb response without blood transfusion. In
this small 12 week study of 186 patients, it was
shown that Epoetin theta is a safe and effective
treatment for anaemia due to nonplatinum chemo-
therapy in patients with solid tumours or non-
myeloid haematological malignancies.
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Popova Plovdiv, N. Tzvetkov Pleven, L. Gercheva
Varna, H. Markova Shumen, V. Taskova Varna; Chile:
O. Giannini Tassara Viña del Mar; India: G. Narayanan
Kerala, B. Vadhiraja Karnataka, C. Goswami West
Bengal, V. Gupta Gujarat, M. Walia Delhi, K. Prabhash
Maharastra, A. Ranade Pune, V. Choudhary Chattis-
ghar, H. Malhotra Rajasthan; Moldova: I. Corcimaru
Chisinau; Romania: C. Volovat Iasi, G. Barca Bucuresti,
R. Stoia Bucuresti, E. Gheorghita Brasov, R-G. Mihaila
Sibiu, M. Gavanescu Targu Jiu; Russia: D. Korman
Moscow, E. Voznyi Moscow, V. Ivanova Moscow, L.
Neluybina Moscow, O. Rukavitsin Moscow, I. Zyuzgin
Saint Petersburg, B. Afanasyev Saint Petersburg, E.
Osmanov Moscow, V. Pavlov Obninsk, I. Lisukov
Novosibirsk, D. Viushkov Omsk, S. Tjulandin Moscow,
A. Agamov Yaroslavl, A. Bakirov Ufa, O. Lipatov Ufa, V.
Shirinkin Orenburg, N. Klimusheva Ekaterinburg,
Mashchuk Krasnodar; Ukraine: B. Veresh Uzhgorod, L.
Chybisov Lugansk, O. Ponomarova Kiev, S. Sivkovych
Kiev, Y. Samokhval Cherkasy, T. Kachmar Lviv, H.
Pylypenko Cherkasy, N Kalinkina Donetsk, N. Tretyak
Kiev, V. Matlan Lviv, P. Kaplan Dnipropetrovsk, I.
Lytvyn Dnipropetrovsk.
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Arch Drug Info 2011;4:33–41The trial was registered in the ISRCTN Register
(http://www.controlled-trials.com); the registration
number is ISRCTN08063129.
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